| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total other expense, net | -3,456 | -3,923 | -8,166 | -2,265 |
| Net income before taxes | 25,909 | 30,920 | 4,268 | 6,551 |
| Income tax benefit (expense) | -364,986 | 2,733 | 388 | -328 |
| Net income | 390,895 | 28,187 | 3,880 | 6,879 |
| Basic (in dollars per share) | 2.69 | 0.19 | 0.03 | 0.05 |
| Diluted (in dollars per share) | 2.43 | 0.17 | 0.02 | 0.04 |
| Us-gaap_weightedaveragenumberofdilutedsharesoutstanding | 160,997,977 | 162,559,404 | 160,714,388 | 159,423,571 |
| Weighted-average common shares outstanding (in shares) | 145,416,901 | 146,739,833 | 145,102,479 | 144,727,482 |
TG THERAPEUTICS, INC. (TGTX)
TG THERAPEUTICS, INC. (TGTX)